Abstract | BACKGROUND:
Certolizumab pegol (CZP) is Food and Drug Administration (FDA)-approved to treat Crohn's disease (CD). However, the efficacy and safety of CZP outside clinical trials are not well established. AIM: To report the efficacy, safety and predictors of response to CZP in CD patients treated during a 6-year period since FDA-approval at a tertiary care centre. METHODS: All CD patients who received CZP at our institution between 2008 and 2013 were evaluated through retrospective medical record-based review of steroid-free complete response (SCR), loss of response and safety. RESULTS: A total of 358 patients were included. One hundred twelve patients (31.3%) and 189 (52.8%) received CZP as their second and third biological agent, respectively. The probability of SCR at 26 week was 19.9% (95% CI, 15.9-24.5). The probability of survival free of loss of response at 2 year was 45.7% (95% CI, 32.5-59.5). A predictor of SCR was age at CD diagnosis of >40 years old (hazard ratio, HR relative to those <17, 4.69; 95% CI, 1.75-12.61). Negative predictors included present perianal fistula (HR, 0.39; 95% CI, 0.16-0.98) and prior primary nonresponse to adalimumab (ADA; HR relative to secondary loss of response, 0.18; 95% CI, 0.04-0.76). Twenty-three patients (6.4%) experienced serious adverse events and 19 patients (5.3%) discontinued CZP due to adverse events. CONCLUSIONS:
|
Authors | W Moon, L Pestana, B Becker, E V Loftus Jr, K A Hanson, D H Bruining, W J Tremaine, S V Kane |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 42
Issue 4
Pg. 428-40
(Aug 2015)
ISSN: 1365-2036 [Electronic] England |
PMID | 26081839
(Publication Type: Journal Article)
|
Copyright | © 2015 John Wiley & Sons Ltd. |
Chemical References |
- Biological Products
- Adalimumab
- Certolizumab Pegol
|
Topics |
- Adalimumab
(therapeutic use)
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Biological Products
(therapeutic use)
- Certolizumab Pegol
(adverse effects, therapeutic use)
- Crohn Disease
(drug therapy)
- Female
- Humans
- Male
- Middle Aged
- Rectal Fistula
(pathology)
- Retrospective Studies
- Tertiary Care Centers
- Treatment Outcome
- United States
- United States Food and Drug Administration
- Young Adult
|